Fenoldopam use in a burn intensive care unit: A retrospective study

BMC Anesthesiology

Volumn 10, Issue , 2010, Pages

  Simmons, John W ^a   Chung, Kevin K ^a,d   Renz, Evan M ^a,c,d   White, Christopher E ^a,c   Cotant, Casey L ^b   Tilley, Molly A ^b   Hardin, Mark O ^a   Jones, John A ^a   Blackbourne, Lorne H ^a   Wolf, Steven E ^a,c  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; FENOLDOPAM MESILATE; HYPERTENSIVE FACTOR; NORADRENALIN; VASOPRESSIN;

ADULT; ARTICLE; BURN; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

EID: 77954875784     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-10-9     Document Type: Article

References (55)

1. Lokhandwala MF. Preclinical and clinical studies on the cardiovascular and renal effects of fenoldopam: a DA-1 receptor agonist. Drug Development Research 1987, 10(3):123-134.
2. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Diseases 1998, 31(5):743-755.
3. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 1991, 5(15):3023.
4. Conger J, et al. Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Investig 1995, 96(1):631. 10.1172/JCI118078, 185238, 7542287.
5. Murphy M, et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation 1987, 76(6):1312-1318.
6. Mathur V, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999, 27(9):1832. 10.1097/00003246-199909000-00021, 10507606.
7. Caimmi PP, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothor and Vasc Anesthesia 2003, 17(4):491-494.
8. Ranucci M, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thoracic Surg 2004, 78(4):1332-1337.
9. Tumlin J, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy 1. Am Heart J 2002, 143(5):894-903. 10.1067/mhj.2002.122118, 12040355.
10. Allaqaband S, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheterization and Cardiovascular Interventions 2002, 57(3). 10.1002/ccd.10323, 12410497.
11. Stone G, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. Am Med Assoc 2003, 2284-2291.
12. Briguori C, et al. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004, 44(4):762-765. 10.1016/j.jacc.2004.04.052, 15312855.
13. Halpenny M, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001, 56(10):953-960. 10.1046/j.1365-2044.2001.02220.x, 11576097.
14. Halpenny M, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2006, 19(01):32-39.
15. Bove T, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005, 111(24):3230. 10.1161/CIRCULATIONAHA.104.509141, 15967861.
16. Tumlin J, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Diseases 2005, 46(1):26-34.
17. Kini A, et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheterization and Cardiovascular Interventions 2002, 55(2). 10.1002/ccd.10038, 11835641.
18. Lechner BL, Pascual JF, Roscelli JD. Failure of fenoldopam to control severe hypertension secondary to renal graft rejection in a pediatric patient. Mil Med 2005, 170(2):130-132.
19. Costello JM, et al. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Ped Crit Care Med 2006, 7(1):28.
20. Landoni G, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Diseases 2007, 49(1):56-68.
21. Coca S, et al. Contribution of acute kidney injury toward morbidity and mortality in burns: a contemporary analysis. Am J Kidney Diseases 2007, 49(4):517-523.
22. Ostermann M, Chang R. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007, 35(8):1837. 10.1097/01.CCM.0000277041.13090.0A, 17581483.
23. Palmieri T, Lavrentieva A, Greenhalgh D. Assessment of acute kidney injury with modified RIFLE criteria in critically ill pediatric burn patients. Crit Care 2009, 13(Suppl 1):P265.
24. Bihorac A, et al. Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg 2009, 249(5):851. 10.1097/SLA.0b013e3181a40a0b, 19387314.
25. Hoste E, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10(3):R73. 10.1186/cc4915, 1550961, 16696865.
26. Kuitunen A, et al. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thoracic Surg 2006, 81(2):542-546.
27. Mehta R, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31. 10.1186/cc5713, 2206446, 17331245.
28. Chung K, et al. Continuous renal replacement therapy improves survival in severely burned military casualties with acute kidney injury. J Trauma 2008, 64(2):S179. 10.1097/TA.0b013e3181608676, 18376163.
29. Chung K, et al. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care 2009, 13(3):R62. 10.1186/cc7864, 2717417, 19409089.
30. Shore S, et al. Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease. Am J Cardiol 2001, 88(5):591-594. 10.1016/S0002-9149(01)01751-9, 11524081.
31. Wernovsky G, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circul 1995, 92(8):2226.
32. Zuppa AF, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004, 32(11):2318.
33. Tsujimoto H, et al. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res 2004, 10(4):229.
34. Cruz DN, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301(23):2445. 10.1001/jama.2009.856, 19531784.
35. Baker SP, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974, 14(3):187.
36. Baker SP, O'Neill B. The injury severity score: an update. J Trauma 1976, 16(11):882. 10.1097/00005373-197611000-00006, 994270.
37. Lopes J, et al. Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the acute kidney injury network classifications. Crit Care 2008, 12(4):R110. 10.1186/cc6997, 2575599, 18755026.
38. Costantini T, et al. Redefining renal dysfunction in trauma: implementation of the acute kidney injury network staging system. J Trauma 2009, 67(2):283. 10.1097/TA.0b013e3181a51a51, 19667880.
39. Conger JD, Robinette JB, Schrier RW. Smooth muscle calcium and endothelium-derived relaxing factor in the abnormal vascular responses of acute renal failure. J Clin Investig 1988, 82(2):532. 10.1172/JCI113628, 303544, 3261301.
40. Conger JD, Falk SA. Abnormal vasoreactivity of isolated arterioles from rats with ischemic acute renal (ARF). J Am Soc Nephrol 1993, 4:733A.
41. Shibouta Y, et al. Pathophysiological role of endothelin in acute renal failure. Life Sci 1990, 46(22):1587-1595. 10.1016/0024-3205(90)90392-5, 1972258.
42. DiBona GF, Sawin LL. The renin-angiotensin system in acute renal failure in the rat. Lab Investig: J Tech Methods and Pathol 1971, 25(6):528.
43. Hatziantonious C, Papankolaou N. Renal effects of the inhibitor of thromboxane A2-synthatse OKY-046. Experientia (Basel) 1986, 42:613-615.
44. Macedo E, Mehta RL. Prerenal failure: from old concepts to new paradigms. Current Opin in Crit Care 2009, 15(6):467-473.
45. Ramaswamy D, et al. Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Physiol-Renal Physiol 2002, 282(2):271.
46. Conger JD, et al. Responses to hemorrhagic arterial pressure reduction in different ischemic renal failure models. Kidney Int 1994, 46(2):318-323. 10.1038/ki.1994.277, 7967342.
47. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002, 62(5):1539-1549. 10.1046/j.1523-1755.2002.00631.x, 12371954.
48. Okusa MD, et al. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol-Renal Physiol 1999, 277(3):404.
49. Tumlin JA. Impaired blood flow in acute kidney injury: pathophysiology and potential efficacy of intrarenal vasodilator therapy. Curr Opin in Crit Care 2009, 15(6):514-519.
50. Han G, et al. A novel transduction mechanism mediating dopamine-induced vascular relaxation: opening of BKCa channels by cyclic AMP-induced stimulation of the cyclic GMP-dependent protein kinase. J Cardiovas Pharmacol 1999, 34(5):619.
51. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesthesia & Analgesia 1992, 74(1):72.
52. Riedela N, Shawc A. Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. Kidney Blood Press Res 2006, 29:165-174. 10.1159/000095350, 16931895.
53. Drager LF, et al. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dialysis Transplantation 2004, 19(7):1803.
54. Wu H, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Investig 2007, 117(10):2847-2859. 10.1172/JCI31008, 1974864, 17853945.
55. Kellum J. Prophylactic fenoldopam for renal protection? No, thank you, not for me-Not yet at least. Crit Care Med 2005, 33(11):2681. 10.1097/01.CCM.0000186743.30595.AA, 16276198.